Whiplash
Catherine Coulter
Putnam, Jun 15 2010, $26.95
ISBN: 9780399156533
Yale Professor Edward Kender has colon cancer in which the drug Culovort he receives as part of his treatment seems to be working when he is informed production by German firm Schiffer Hartwin is nonexistent. Stunned he assumes the pharmaceutical industry is playing death squad to drum up profits. He hires private investigator Erin Pulaski to make an inquiry into the firm. She breaks in and enters the head office of the American subsidiary in Stone Bridge, Connecticut in order to hack into the files of the local CEO Caskie Royal. She finds info on plans to stop the Cartwright Labs in Bartonville, Missouri from manufacturing the drug; as well as stopping it in Spain in favor of a French firm Labortoires Anconder’s drug Eloxium. However, Royal and production manager Carla Alvarez arrive and discuss what they are doing with the firm and then have sex..
The next day she learns that the firm’s troubleshooter was murdered near where she downloaded computer data that made no sense to her. Meanwhile, the FBI sends married couple Agents Sherlock and Savich to Stone Bridge to assist FBI agent Bowie Richards with the homicide. They begin to find troubles with the pharmaceutical company while Pulaski wonders what to do with her illegal download; Pulaski becomes their prime suspect. Savich also investigates the poisoning of a lobbyist whose real target may have been aimed at a US Senator.
This is a great timely entry in the long running S&S FBI police procedural series due to the pharmaceutical connection as much as the freshness brought forth by Richards and more so by Erin who knows her B&E was stupid but felt strongly that they needed to expose true death squad bottom lines. Fast-paced from the onset, the second case takes somewhat of a back seat though it is well written and quite exciting too. Fans of the series will relish this strong entry while newcomers will find Whiplash a winner too.
Harriet Klausner
Sunday, April 25, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment